What question did this study set out to answer?

To update clinical recommendations and evaluate contemporary evidence regarding the benefits and risks of hormone therapy for managing menopausal symptoms and related health conditions.

July 1, 2022Menopause The Journal of The North American Menopause Society

The 2022 hormone therapy position statement of The North American Menopause Society

View Full Paper

Ask AI

Bookmark

Authors

SFStephanie S. FaubionMayo Clinic CCCarolyn CrandallUniversity of California, Los Angeles LDLori A. DavisGoogle (United States)

Discussion

Member takes

Implication

Expert consensus guideline demonstrates favorable benefit-risk profiles for hormone therapy in menopausal women under age sixty, highlighting the importance of individualized treatment timing.

Key Points

To update clinical recommendations and evaluate contemporary evidence regarding the benefits and risks of hormone therapy for managing menopausal symptoms and related health conditions.
An expert advisory panel of women's health clinicians and researchers reviewed post-2017 literature and graded the strength and quality of the evidence.
Consensus recommendations were developed by the advisory panel and approved by the North American Menopause Society Board of Trustees.
Systemic hormone therapy remains the most effective intervention for vasomotor symptoms and genitourinary syndrome of menopause, while effectively preventing bone loss and fractures.
The benefit-risk ratio is favorable for women younger than 60 years or within 10 years of menopause onset, but becomes less favorable with older age or later initiation due to higher risks of coronary heart disease, stroke, venous thromboembolism, and dementia.
Low-dose vaginal estrogen, vaginal dehydroepiandrosterone, or oral ospemifene are recommended for genitourinary syndrome of menopause unresponsive to over-the-counter options when systemic therapy is not indicated.

Cite This Study

Faubion et al. (2022) studied this question.

synapsesocial.com/papers/69d74e89df21310ab048f4d5 https://doi.org/10.1097/gme.0000000000002028

View Full Paper

Ask AI

Bookmark

Implication

Expert consensus guideline demonstrates favorable benefit-risk profiles for hormone therapy in menopausal women under age sixty, highlighting the importance of individualized treatment timing.

The 2022 hormone therapy position statement of The North American Menopause Society

Discussion

Member takes

Implication

Key Points

Cite This Study

The 2022 hormone therapy position statement of The North American Menopause Society

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider